Загрузка...
Metformin causes a futile intestinal–hepatic cycle which increases energy expenditure and slows down development of a type 2 diabetes-like state
OBJECTIVE: Metformin, the first line drug for treatment of type 2 diabetes, suppresses hepatic gluconeogenesis and reduces body weight in patients, the latter by an unknown mechanism. METHODS: Mice on a high fat diet were continuously fed metformin in a therapeutically relevant dose, mimicking a ret...
Сохранить в:
Опубликовано в: : | Mol Metab |
---|---|
Главные авторы: | , , , , , , , , , , , |
Формат: | Artigo |
Язык: | Inglês |
Опубликовано: |
Elsevier
2017
|
Предметы: | |
Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5485244/ https://ncbi.nlm.nih.gov/pubmed/28702329 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molmet.2017.05.002 |
Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|